| Species |
Human |
| Protein Construction |
FGFR1 beta (IIIc) (Lys158-Thr355)
Accession # P11362-7 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized AntiFGFR1 Anitibody, hFc Tag at 2μg/ml (100μl/Well) on the plate can bind FGFR1 beta (IIIc), His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
25.23 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fibroblast growth factor receptor 1 (FGFR1) transmits signals through the plasma membrane regulating essential cellular processes like division, motility, metabolism, and death. Overexpression of FGFR1 is observed in numerous tumors and thus constitutes an attractive molecular target for selective cancer treatment. |
| Synonyms |
FGFR-1; BFGFR; bFGF-R-1; FLT-2;N-sam; CD331 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
